ICC Beer Partnership Focused on Budweiser 0.0 Could Be A Game Changer For Anheuser-Busch InBev (ENXTBR:ABI)

• Earlier in December 2025, the International Cricket Council announced that AB InBev will become the Official Beer Partner for all major ICC tournaments from 2026 to 2027, led by Budweiser 0.0 in India and supported by other brands across Europe and Africa.
• This partnership places AB InBev’s no-alcohol and lower-ABV portfolio at the heart of global cricket events, expanding exposure to millions of fans across key beer-drinking markets.
• We’ll now examine how this ICC partnership, centered on Budweiser 0.0 and other brands across regions, may influence AB InBev’s investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Anheuser-Busch InBev Investment Narrative Recap

To own AB InBev, you need to believe its global brands, premiumization and no and low alcohol expansion can offset volume and macro pressures while it steadily reduces high debt. The ICC cricket partnership reinforces the no alcohol growth angle and improves brand visibility in emerging markets, but it does not materially change the near term focus on deleveraging or the key risk of demand softness in markets like China and Brazil.

The most relevant recent development alongside the ICC deal is AB InBev’s extension of its long running FIFA partnership, which also leans on megabrands such as Budweiser and Michelob ULTRA. Together, these global sports tie ups support the catalyst of premium and no and low alcohol portfolio expansion, but they sit against ongoing concerns that shifting consumer preferences and weaker on premise demand could still pressure mainstream lager volumes and margins.

However, investors also need to be alert to the risk that continued shifts toward non alcoholic alternatives and craft could...

Read the full narrative on Anheuser-Busch InBev (it's free!)

Anheuser-Busch InBev's narrative projects $67.7 billion revenue and $9.7 billion earnings by 2028. This requires 5.0% yearly revenue growth and a $2.6 billion earnings increase from $7.1 billion today.

Uncover how Anheuser-Busch InBev's forecasts yield a €68.58 fair value, a 24% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members have shared 11 fair value estimates for AB InBev, ranging from €51.93 to €143.44, highlighting very different views on upside. As you weigh those perspectives, consider how much confidence you place in AB InBev’s ability to grow its no and low alcohol portfolio through partnerships like the ICC deal while still managing high leverage and potential volume headwinds in key emerging markets.

Explore 11 other fair value estimates on Anheuser-Busch InBev - why the stock might be worth over 2x more than the current price!

Build Your Own Anheuser-Busch InBev Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Anheuser-Busch InBev research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Anheuser-Busch InBev research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Anheuser-Busch InBev's overall financial health at a glance.

Interested In Other Possibilities?

Our top stock finds are flying under the radar-for now. Get in early:

• These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com